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Thymic stromal lymphopoietin (TSLP)
Treatment
TSLP receptor (TSLPR)
a b s t r a c t
TSLP is an epithelial cell-derived cytokine synthesized in response to various stimuli, including protease
allergens and microorganisms like viruses and bacteria. Biological functions of TSLP require hetero-
dimer formation between the TSLP receptor (TSLPR) and IL-7 receptor-a, which polarize dendritic cells
to induce type 2 inflammation and directly expand and/or activate Th2 cells, group 2 innate lymphoid
cells, basophils, and other immune cells. TSLP is thus considered a master regulator of type 2 immune
responses at the barrier surfaces of skin and the respiratory/gastrointestinal tract. Indeed, genetic,
experimental, and clinical evidence suggests that the TSLP-TSLPR pathway is associated with the
pathogenesis of allergic diseases such as atopic dermatitis (AD) and asthma. Tezepelumab (AMG-157/
MEDI9929) is a human anti-TSLP antibody that prevents TSLP-TSLPR interactions. A phase 2 trial for
moderate to severe AD showed that a greater but not statistically significant percentage of
tezepelumab-treated patients showed clinical improvements compared to the placebo group. A phase 2
trial for uncontrolled, severe asthma showed significant decreases in asthma exacerbation rate and
improved pulmonary function and asthma control for tezepelumab-treated patients. Levels of bio-
markers of type 2 inflammation, such as blood/sputum eosinophil counts and fraction of exhaled nitric
oxide decreased, however, clinical efficacy was observed irrespective of the baseline levels of these
biomarkers. A blockade of the TSLP-TSLPR pathway likely will exert significant clinical effects on AD,
asthma, and other allergic diseases. The efficacy of anti-TSLP antibodies compared to other biologics
needs to be further examined.
Copyright © 2020, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
TSLP is a secreted molecule of a murine thymic stromal cell line
that was identified more than two decades ago. Since then, a hu-
man orthologue has also been identified.1,2 TSLP has been widely
studied as a master regulator of Th2-type (type 2) immune re-
sponses occurring at barrier surfaces such as the skin, lungs, and
gut. TSLP produced by epithelial cells at barrier surfaces activates
TSLP receptor (TSLPR)-expressing DCs to induce functional Th2
cells.3 In addition, TSLP is known to be associated with other dis-
eases, including autoimmune disorders and cancer.4 Such a broad
pathophysiological profile has motivated the therapeutic targeting
of TSLP- and TSLPR-mediated signaling in type 2 cytokine-
mediated allergic diseases. In this review, we summarize the
known molecular mechanism of TSLP-TSLPR-mediated signaling
and its pathological roles in atopic dermatitis (AD) and asthma to
convey the potential usefulness of the TSLP-TSLPR signaling
pathway as a therapeutic target for these diseases.
Biological properties of TSLP and TSLPR
TSLP is a member of the IL-2 cytokine family and was originally
classified as a molecule that can stimulate murine thymocytes and
promote B cell proliferation and development.2 A human homolog
was subsequently identified, and further characterization of this
* Corresponding author. Division of Pulmonary Medicine, Department of Medi-
cine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa,
259-1193, Japan.
** Corresponding author. Department of Dermatology, Kyoto University Graduate
School of Medicine, 54 Shogoin Kawahara- cho, Sakyo-ku, Kyoto, 6068507, Japan.
E-mail addresses: kaba@kuhp.kyoto-u.ac.jp (K. Kabashima), ko-asano@tokai-u.
jp (K. Asano).
Peer review under responsibility of Japanese Society of Allergology.
1 These authors equally contributed to this work.
Contents lists available at ScienceDirect
Allergology International
journal homepage: ht tp: / /www.elsevier .com/locate/al i t
https://doi.org/10.1016/j.alit.2020.01.001
1323-8930/Copyright © 2020, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Allergology International 69 (2020) 197e203
cytokine revealed a four-helix bundle structure containing six
conserved cysteine residues and multiple potential sites for N-
linked carbohydrate additions. In spite of only 43% amino acid
identity, human and murine TSLP share a significant degree of
functional homology.1
Epithelial cells in the lungs, skin, and gastrointestinal tract are
reported to be the primary source of TSLP during homeostatic and
inflammatory conditions, although other immune cells such as DCs,
basophils, and mast cells can also produce TSLP.5e7 In addition,
TSLP expression in target cells can be induced by several cytokines,
such as TNF-a and IL-1b,8 respiratory viruses,9 bacterial and fungal
products,10,11 mechanical injury,12 allergens,13 cigarette smoke ex-
tracts,14 and proteases such as tryptase and papain.15
TSLP binds to a heterodimeric receptor consisting of the IL-7
receptor a-chain (IL-7Ra) and the TSLPR chain, which is closely
related to the common receptor g chain (gc), in order to exert its
biological activity on a broad range of cell types. TSLPR alone has a
low affinity for TSLP but binding of TSLPR to IL-7Ra creates a high
affinity binding site for TSLP and triggers signaling.16 In mice, the
TSLP-signal transducer and activator of transcription (STAT) 5 axis
in DCs is a critical pathway for promoting type 2 immune responses
at barrier surfaces.17,18
TSLP is a cytokine involved in bothphysiological andpathological
immunity-related activities. TSLP has homeostatic activities due to
its expression by Hassal corpuscles in the thymus and regulates the
capacity of DCs and plasmacytoid DCs to drive development of
Tregs.19,20 TSLPalsopromoteshomeostatic polyclonal expansionof T
cells in the absence of foreign antigens.21 In the gut, TSLP constitu-
tively expressed by intestinal epithelial cells can act on non-
inflammatory DCs that have reduced abilities to produce IL-
12p7022 and drive the differentiation of inducible Tregs.23 In
contrast, in inflammatory conditions, TSLP stimulates DCs to upre-
gulate co-stimulatorymolecules like OX40L, CD80, and CD867. TSLP-
treatedDCs candrive activity of IL-4, IL-5, and IL-13-producing CD4þ
T cells in vitro. In addition to the effects of TSLP on Th2 cell polari-
zation through antigen-presenting cells,24,25 TSLP candirectlyact on
Tcells, including CD4þ Tcells, CD8þ Tcells, and Tregs. TSLP also plays
an essential role inTreg-cell-dependent immunehomeostasis in the
skin through TSLPR signaling in Treg cells. Loss of TSLPR signaling in
skin-associated Tregs inhibits their activation and permits rapid
progression from skin pro-inflammatory responses to lethal sys-
temic inflammation.26 TSLP can also promote Th2 cytokine re-
sponses through its actions on mast cells, ILCs, epithelial cells,
macrophages, and basophils.27e31 In addition, TSLP can directly act
on a subset of sensory neurons to induce itch in AD.15 In murine
models of allergic disease, TSLP can induce differentiation of Th2
cells and Th9 cells through its effects on DCs and T cells.32,33 TSLP
signaling in basophils is important in murine models of experi-
mental eosinophilic esophagitis and food allergies.34,35
Two isoforms of TSLP, short and long isoforms, have been
described in mice, but the functional consequences of this variation
are unclear. In humans, the main isoform expressed during steady
state conditions is the short form of TSLP, whereas the long form of
TSLP is upregulated in inflammatory conditions36,37. In addition,
there is evidence that in pathological conditions, TSLP can be
cleaved by several endogenous proteases.38,39 For example, in celiac
disease patients, the protease furin, which is upregulated in patient
biopsies, can cleave the long isoform of TSLP, producing 10 kDa and
4 kDa fragments with different activities on human peripheral
blood mononuclear cells compared to mature TSLP.40 Cleavage of
TSLP by serine proteases may also regulate TSLP protein levels or
function in the skin. However, since the expression patterns and
biological properties of these two different isoforms of TSLP seem
to be distinct, these two TSLP isoforms should be analyzed sepa-
rately in future studies.
TSLP in AD
AD is a common chronic skin inflammatory disorder charac-
terized by recurrent eczema accompanied by an intractable itch
leading to an impaired quality of life. The complex interplay among
skin barrier dysfunction, immunological derangement, and pruri-
tus contributes to the development, progression, and chronicity of
AD.41e43 AD also has a complex etiology, including genetic and
environmental factors, that leads to abnormalities in epidermal and
immune system function.44,45
TSLP polymorphisms in AD patients
Polymorphisms in the TSLP gene are associated with an
increased risk of development and progression of AD. AD is
significantly associated with three TSLP-single nucleotide poly-
morphisms (SNPs) (rs1898671, rs11466749, and rs10043985), four
IL7R-SNPs (rs12516866, rs102113865, rs1389832, and rs10058453),
and three TSLPR-SNPs (rs36139698, rs36177645, and rs36133495)
in European American populations.46
The role of TSLP in AD pathogenesis
Blood serum levels of TSLP in children and adults with AD are
significantly increased compared to healthy subjects.47,48 In addi-
tion, TSLP is expressed in keratinocytes of epidermal apical layers in
skin lesions of acute and chronic AD patients, but not in non-
lesional skin and not in lesions of patients with nickel-induced
allergy contact dermatitis or cutaneous lupus erythematosus.7
The role of TSLP in acquired immune cells in AD
Induced expression of TSLP in mouse epidermal keratinocytes
upon topical application of MC903, a low calcemic analogue of
vitamin D3, triggers AD and aggravates experimental allergic
asthma, indicating an important role of keratinocyte-produced
TSLP in the link between AD and asthma.49,50 The significance of
TSLP in the pathogenesis of AD has been confirmed using trans-
genic mice in which selective overexpression of TSLP in the skin
caused spontaneous AD-like dermatitis.51 TSLP-TLSPR in Langer-
hans cells as antigen-presenting cells in the epidermal signaling
pathway is critical for induction of Th2 type immune responses in
an ovalbumin application-inducedmurinemodel of AD52 (Fig. 1). In
addition to antigen presenting cells, circulating CD4þ T cells in AD
patients show high levels of TSLPR expression compared to healthy
subjects and the level of circulating TSLPRþ CD4þ T cells correlates
with serum CCL17/TARC and IgE levels53 and eosinophil counts,
suggesting that TSLPR is a potential therapeutic target for AD.
TSLP and innate and other cell populations in AD
In addition to acquired immune cell populations, basophils and
ILCs are crucial innate cell populations downstream of TSLP.54 TSLP
promotes peripheral basophilia and TSLPR-expressing basophils
can restore Th2-dependent immunity in mice.28 Among ILC sub-
populations, group 2 ILCs (ILC2s) are present in healthy human skin
and are enriched in lesional skin of AD patients. ILC2s are also found
in healthy murine skin and are critical for the development of
inflammation in a murine model of AD-like dermatitis induced by
MC903 application27 (Fig. 1).
TSLPR and IL-7Ra transcripts are expressed in mouse and hu-
man dorsal root ganglion cells and TSLPR expression is localized to
a subset of primary afferent nerve terminals in mouse skin. Injec-
tion of TSLP into mouse cheek skin induced scratching behavior in
an IL-7Ra and primary afferent neuron-dependent manner. TSLPR
activation of primary afferent sensory neurons requires the ion
channel transient receptor potential (TRP)A1 but not TRPV115
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(Fig. 1). These data identify TSLP as a novel endogenous pruritogen
and suggest that keratinocyte-derived TSLP can be a therapeutic
target against pruritus in AD.
Effects of the skin microbiome on TSLP production in AD
Staphylococcus aureus (S. aureus) is detected in 90% of lesional
skin of patients with AD and is rarely detected in healthy skin55.
Similarly, analysis of the skin microbiome using next-generation
sequencing detected S. aureus in patients with AD, and its relative
abundance is greatly increased during disease flares compared to
baseline conditions,56 suggesting that skin inflammation may
accelerate the colonization of S. aureus or vice versa.57
In the context of inflammation promotion during AD, S. aureus
produces a protease enabling it to penetrate into the dermis of AD
patients or mice with filaggrin loss-of-function mutations.58,59
S. aureus penetration results in increased production of type 2 cy-
tokines like TSLP, IL-4, and IL-1358. S. aureus cell wall components
also signal through toll-like-receptor 2/6 and induce TSLP pro-
duction in keratinocytes10 (Fig. 1).
Anti-TSLP antibody therapy for AD
As above described, TSLP plays a critical role in the pathogenesis
of AD and atopic march. TSLP is released by epidermal keratino-
cytes upon various kind of stimulation. In turn, TSLP favors Th2
responses and pruritus pathway activity by affecting a subset of
sensory neurons. TSLP is thus a promising therapeutic target for AD
pathogenesis. Tezepelumab (AMG-157/MEDI9929) is a human
monoclonal antibody targeting circulating TSLP. Tezepelumab has
completed phase 1 (NCT00757042) and phase 2a (NCT02525094)
randomized, double-blinded, placebo-controlled studies evaluate
its efficacy and safety in subjects withmoderate to severe AD. In the
phase 2a study (NCT02525094), 113 patients were randomized 1:1
and provided either 280 mg of subcutaneous tezepelumab or a
placebo every 2 weeks along with class 3 topical corticosteroids
(TCS). The primary endpoint was the week 12 response rate, with a
goal of a 50% reduction in the Eczema Area and Severity Index
(EASI50). Greater but not statistically significant percentages of
tezepelumab plus TCS-treated patients achieved EASI50 (64.7%)
versus placebo plus TCS patients (48.2%; P ¼ 0.091) (Table 1).60
Another study with the anti-TSLP drug MK-8226 was performed
in a phase 1b trial (NCT01732510) but was stopped in the middle of
the trial and data not reported.
TSLP in asthma
Asthma is a chronic lung disease characterized by chronic
airway inflammation, airway hyperresponsiveness, and variable
obstruction. The most common molecular mechanism underlying
asthma is Th2 (type 2) inflammation mediated by type 2 cytokines,
such as IL-4, IL-5, and IL-13, which are mainly derived from Th2
cells and ILC2s. However, some patients with asthma have no
Fig. 1. The role of TSLP in AD pathogenesis. Keratinocytes produce TSLP in response to exposure to allergens such as house dust mite, S. aureus proteases, and mechanistic injury
caused by scratching. TSLP acts on TSLPR in epidermal LCs to induce Th2 immune responses in the skin, draining the lymph nodes. TSLP also directly acts on Th2 cells to produce Th2
cytokines, such as IL-4, IL-5, IL-13 and IL-31 TSLP acts on ILC2s in the skin to produce Th2 cytokines such as IL-5 and IL-13. Th2 cytokines released in lesional skin provoke pruritus,
which induces scratching and the regional production of TSLP. In addition, TSLP directly stimulates TRPA1þ sensory nerves to induce itch in AD skin.
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evidence of type 2 inflammation and have non-Th2 (non-type 2)
inflammation associated with IFN-g or IL-17 derived from Th1 cells,
Th17 cells, or ILC3s.61 These different inflammation patterns cause
heterogeneity of clinical phenotypes of asthma.
TSLP polymorphism in asthma
Genome-wide association studies (GWASs) of asthma identified
a single nucleotide polymorphism in the TSLP locus (rs1837253)
that is associated with an increased risk of asthma in North
American populations.62 Similarly, a GWAS study of Japanese
asthmatic population indicated that the SNP of the TSLP locus
(rs1837253) is associated with susceptibility to adult asthma.63 This
locus is located 5.7 kb upstream of the transcription initiation site
of TSLP and was related to airway hyperresponsiveness in a
candidate gene approach study.64
The role of TSLP in the pathogenesis of asthma
An early study utilizing in situ hybridization and immunohis-
tochemistry demonstrated that the number of TSLP mRNA-
expressing cells within the bronchial epithelium and submucosa
is significantly increased in patients with asthma compared to
normal control subjects.65 In addition, bronchial epithelial, endo-
thelial, and immune cells were shown to express TSLP.65 TSLP
expression levels are also significantly increased in airway epithe-
lium and lamina propria of asthmatic patients, especially those
with severe asthma, in spite of high-dose inhaled corticosteroid
therapy.66 Furthermore, TSLP concentrations in BAL fluids are
significantly elevated in asthmatic patients.67 These studies thus
suggest that expression levels of TSLP are correlated with the
severity of airflow obstruction independent of corticosteroid
therapy.
The effect of TSLP on acquired immune cells in asthma
Mouse models of OVA-induced allergic airway inflammation
show increased TSLP expression in lungs. In addition, TSLPR-
deficient mice show significant suppression of OVA-induced type
2 inflammation.13 Mice overexpressing lung-specific TSLP (SPC-
TSLP mice) spontaneously develop type 2 airway inflammation
associated with infiltration of Th2 cells and increased serum IgE
levels.13 Mechanistically, TSLP induces expression of OX40L by
dendritic cells, which triggers Th2 cell polarization68 and the pro-
liferation of and IL-4 expression by CD4þ T cells.25,69,70
The role of TSLP on innate immunity and cell populations in asthma
(Fig. 2)
ILC2s play an important role in type 2 inflammation in asthma,
especially eosinophilic asthma, severe asthma, and virus-induced
asthma exacerbation.71 Although TSLP does not induce type 2
cytokine production by lung ILC2s, TSLP supports survival of ILC2s,
along with IL-2 and IL-7.72 In contrast, IL-33 strongly induces pro-
liferation and type 2 cytokine production by ILC2s. Interestingly,
the combination of TSLP with IL-33 has a synergistic effect on
proliferation and type 2 cytokine production of both mouse and
human ILC2s.73,74 Furthermore, TSLP activates the anti-apoptotic
Fig. 2. The role of TSLP in asthma pathogenesis. TSLP stimulates DCs, CD4þ T cells, mast cells, and basophils, which promote allergen-induced Th2 cell-mediated immune responses
in airways. Furthermore, TSLP and IL-33 activate ILC2s, enhancing ILC2-mediated immune responses and corticosteroid resistance.
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molecule Bcl-xL via the STAT5 pathway in ILC2s, which induces
resistance to corticosteroids.75 TSLP also induces corticosteroid
resistance in human ILC2s via STAT5 and MAP kinase,74 with the
number of ILC2s significantly increased in the sputum of patients
with severe asthma.76 The TSLP-ILC2 pathway thus appears
involved in the pathophysiology of corticosteroid-resistant severe
asthma. Many other immune cells also express TSLPR, and mast
cells, eosinophils, and NKT cells all respond to TSLP.77 For example,
TSLP, IL-1b, and TNFa synergistically activate human mast cells and
induce production of type 2 cytokines like IL-5, IL-6, and IL-13.30
Role of TSLP in respiratory viral infection-induced asthma
exacerbation
Respiratory viral infections are a major cause of asthma
exacerbation, and double-strand (ds) RNA, an indicator of viral
infection, increases TSLP expression in bronchial epithelial
cells.78 Importantly, bronchial epithelial cells from patients with
asthma exhibit higher levels of TSLP in response to dsRNA than
bronchial epithelial cells from control subjects.79 In general,
respiratory viruses, such as rhinovirus, respiratory syncytial (RS)
virus, and influenza virus, increase the production of epithelial
cell-derived cytokines, like IL-33, IL-25, and TSLP. In addition,
RS infections induce ILC2, which produces IL-13 and causes
mucin overexpression. In this model system, an anti-TSLP anti-
body or the lack of TSLP in TSLP receptor-deficient mice
reduces the number of IL-13þ ILC2s and reduces mucin
overexpression.80
Anti-TSLP antibody therapy for asthma
Tezepelumab has completed proof-of-concept and phase 2
randomized, double-blinded, placebo-controlled studies for eval-
uation of its efficacy and safety in subjects with asthma. In a proof-
of-concept study (NCT01405963), 700 mg of tezepelumab or a
placebo was intravenously administered every 4 weeks to 31 pa-
tients with mild allergic asthma.81 Allergen inhalation challenges
were performed two weeks before the first dose of tezepelumab,
and on days 42 and 84 of treatment. The primary end point was the
%decrease in FEV1 during the late asthmatic response after allergen
challenge and was lower in the tezepelumab-treated group by
34e46% on days 42 and 84 (P ¼ 0.09 and 0.02, respectively),
compared to the placebo group. Interestingly, early asthmatic re-
sponses were also decreased in the tezepelumab group by 27e31%
(P ¼ 0.05e0.06), suggesting that tezepelumab suppresses TSLP to
activate basophils and/or mast cells.82 Although there were no
significant changes in FEV1 levels possibly due to relatively good
baseline pulmonary function, airway responsiveness to meth-
acholine was significantly improved. Treatment with tezepelumab
decreased eosinophil counts in peripheral blood/sputum, Th2/Th1
cell ratios in peripheral blood, and FeNO, suggesting that tezepe-
lumab attenuates late asthmatic responses through effects on Th2
cells/ILC2s. There were no changes in CD4þCD25þCD127lowFoxp3þ
regulatory T cell frequency.83
In a phase 2 study (NCT02054130), 584 patients with uncon-
trolled asthma who had at least two asthma exacerbations in the
previous year and Asthma Control Questionnaire (ACQ)-6 scores of
at least 1.5 despite combined treatments of medium-to-high doses
of ICS with long-acting b2 agonists, were randomized 1:1:1:1 for
treatment with 70 mg of subcutaneous tezepelumab every 4 weeks
(low-dose), 210 mg tezepelumab every 4 weeks (medium-dose),
280mg tezepelumab every 2weeks (high-dose), or a placebo.84 The
primary endpoint was the asthma exacerbation rate during 52
week-study period, which was 0.26, 0.19, and 0.22 in the low-dose,
medium-dose, and high-dose groups, respectively, compared to
0.67 in the placebo group. FEV1 levels improved in the tezepelumab
group by 0.11e0.15 L more than in placebo group and ACQ-6 scores
were decreased. Blood eosinophil counts, FeNO, and total serum IgE
levels were also decreased, supporting the hypothesis that the anti-
TSLP antibody inhibits type 2 responses. Importantly, suppression
of asthma exacerbation by tezepelumab was observed irrespective
of peripheral blood eosinophil count or FeNO (Fig. 3), in contrast to
previous reports showing that an anti-IL-4 receptor-a antibody and
Fig. 3. Annualized rate of asthma exacerbation at week 52 based on baseline biomarker status in patients treated with tezepelumab or a placebo. Patients with uncontrolled asthma
were randomized 1:1:1:1 for treatment with 70 mg subcutaneous tezepelumab every 4 weeks (low-dose, n ¼ 145), 210 mg tezepelumab every 4 weeks (medium-dose, n ¼ 145),
280 mg tezepelumab every 2 weeks (high-dose, n ¼ 146), or a placebo (n ¼ 148). Annualized rates of asthma exacerbation at week 52 was compared based on peripheral blood
eosinophil counts, FeNO, and Th2 status. A Th2 high status was defined as an IgE level of more than 100 IU/mL and a blood eosinophil count of 140 cells/mL. Reproduced from Ref. 84
with permission.
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anti-IL-5/IL-5 receptor-a antibodies exhibit limited efficacy in non-
type 2 asthma.
Currently, two phase 3 trials for tezepelumab in patients with
uncontrolled, severe asthma are underway. The NAVIGATOR trial
(NCT03347279) will examine > 1000 patients with uncontrolled
asthma under medium to high doses of ICS and other controller(s)
randomized to either subcutaneous tezepelumab or placebo, and
the primary endpoint is the annual asthma exacerbation rate. The
SOURCE trial (NCT03406078) will examine whether tezepelumab
treatment can reduce the required daily doses of oral corticoste-
roids without loss of asthmatic symptom control.
CSJ 117 is a once-daily inhaled formulation of a monoclonal
antibody fragment (Fab) targeting TSLP. A 12-week phase 1 trial
(NCT03138811) in patients with mild asthma has just been
completed, but no data are available yet.
Conclusion
TSLP is considered a master regulator for the transition to type 2
inflammation at the barrier surface of the skin, airways/lungs, and
gut. This hypothesis is supported by genetic, experimental, and
clinical evidence and has nowbeen confirmed by the effects of anti-
TSLP antibody in patients with allergic diseases. However, the
clinical efficacy of thus anti-TSLP antibody in patients with estab-
lished allergic diseases cannot solely be explained by effects on
dendritic cells and Th2 cells and likely involves additional biolog-
ical functions of the TSLP-TSLPR pathway in other immune cells,
such as basophils and non-immune cells such as neurons. Further
study is required to extend the efficacy and the range of anti-TSLP
antibodies in allergic diseases.
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